Novo Nordisk acquires Omeros’ MASP-3 inhibitor Zaltenibart for up to US$ 340 million
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
IND clearance enables initiation of Phase 1c clinical trial in HFpEF patients with elevated endotrophin levels
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
First research project, supported by the Gates Foundation, focuses on developing non-hormonal contraceptives for women in low- and middle-income countries
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Datamatics will automate the Medication Administration Record process by integrating its intelligent automation products, TruBot and TruCap+
Subscribe To Our Newsletter & Stay Updated